Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 1/2014

01-02-2014 | Original Paper

High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection

Authors: Mariette Labots, Tineke E. Buffart, Josien C. Haan, Nicole C. T. van Grieken, Marianne Tijssen, Cornelis J. H. van de Velde, Heike I. Grabsch, Bauke Ylstra, Beatriz Carvalho, Remond J. A. Fijneman, Henk M. W. Verheul, Gerrit A. Meijer

Published in: Cellular Oncology | Issue 1/2014

Login to get access

Abstract

Purpose

The overall survival rate of patients with advanced gastric cancer is poor. Therefore, there is an urgent need for new treatment options for these patients. The identification of drug target genes located on DNA regions exhibiting high-level copy number gains (CNG) may be an effective approach, as has e.g. previously been shown for HER2. The aim of the present study was to identify putative drug targets in patients with gastric cancer by applying this strategy.

Methods

Genome-wide array comparative genomic hybridization (array CGH) data available from 183 primary gastric cancer samples were analyzed through Ingenuity Pathway Analysis (IPA) to assess whether any established or potential anticancer drug target genes showed high-level CNG, including focal amplifications.

Results

A total of 147 high-level gained regions were identified in the gastric cancer samples, harboring 167 genes that had previously been annotated as drug target genes. Thirty (18 %) of these genes showed high-level gains in at least 2 % of the tumors. The identified drug target genes included those for drugs known to be active in advanced (gastric) cancer, targets for targeted therapies in clinical development, as well as targets for drugs currently used for other indications but of potential interest for anticancer treatment. In addition, 12 potential drug target genes were identified, including genes involved in growth factor signaling and cell cycle regulation.

Conclusion

The majority of gastric cancers carried one or more high-level CNGs or focal amplifications encompassing putative drug target genes. A number of the associated drugs are currently not being considered for treatment of gastric cancer. Based on these results we hypothesize that DNA copy number profiling may be a useful tool to identify new drug targets and to guide individualized treatment strategies in patients with gastric cancer.
Appendix
Available only for authorised users
Literature
1.
D. Cunningham, N. Starling, S. Rao, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates, A.R. Norman, Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36–46 (2008)PubMedCrossRef
2.
E. Van Cutsem, V.M. Moiseyenko, S. Tjulandin, A. Majlis, M. Constenla, C. Boni, A. Rodrigues, M. Fodor, Y. Chao, E. Voznyi, M.L. Risse, J.A. Ajani, Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. 24, 4991–4997 (2006)PubMedCrossRef
3.
A.D. Wagner, S. Unverzagt, W. Grothe, G. Kleber, A. Grothey, J. Haerting, W.E. Fleig, Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev., CD004064 (2010)
4.
A.D. Wagner, W. Grothe, J. Haerting, G. Kleber, A. Grothey, W.E. Fleig, Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. 24, 2903–2909 (2006)PubMedCrossRef
5.
V. Catalano, F. Graziano, D. Santini, S. D'Emidio, A.M. Baldelli, D. Rossi, B. Vincenzi, P. Giordani, P. Alessandroni, E. Testa, G. Tonini, G. Catalano, Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br. J. Cancer 99, 1402–1407 (2008)PubMedCentralPubMedCrossRef
6.
P.C. Thuss-Patience, A. Kretzschmar, D. Bichev, T. Deist, A. Hinke, K. Breithaupt, Y. Dogan, B. Gebauer, G. Schumacher, P. Reichardt, Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur. J. Cancer 47, 2306–2314 (2011)PubMedCrossRef
7.
S.J. Gong, C.J. Jin, S.Y. Rha, H.C. Chung, Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett. 214, 215–224 (2004)PubMedCrossRef
8.
K. Fujimoto-Ouchi, F. Sekiguchi, H. Yasuno, Y. Moriya, K. Mori, Y. Tanaka, Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother. Pharmacol. 59, 795–805 (2007)PubMedCrossRef
9.
H. Grabsch, S. Sivakumar, S. Gray, H.E. Gabbert, W. Muller, HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value–conclusions from 924 cases of two independent series. Cell. Oncol. 32, 57–65 (2010)PubMed
10.
C. Gravalos, A. Jimeno, HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 19, 1523–1529 (2008)PubMedCrossRef
11.
M. Tanner, M. Hollmen, T.T. Junttila, A.I. Kapanen, S. Tommola, Y. Soini, H. Helin, J. Salo, H. Joensuu, E. Sihvo, K. Elenius, J. Isola, Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 16, 273–278 (2005)PubMedCrossRef
12.
Y.J. Bang, C.E. Van, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle, J. Ruschoff, Y.K. Kang, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010)PubMedCrossRef
13.
H.H. Hartgrink, C.J. van de Velde, H. Putter, J.J. Bonenkamp, K.E. Klein, I. Songun, K. Welvaart, J.H. van Krieken, S. Meijer, J.T. Plukker, P.J. van Elk, H. Obertop, D.J. Gouma, J.J. van Lanschot, C.W. Taat, P.W. de Graaf, M.F. von Meyenfeldt, H. Tilanus, M. Sasako, Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J. Clin. Oncol. 22, 2069–2077 (2004)PubMedCrossRef
14.
T.E. Buffart, B. Carvalho, N.C. van Grieken, W.N. van Wieringen, M. Tijssen, E.M. Kranenbarg, H.M. Verheul, H.I. Grabsch, B. Ylstra, C.J. van de Velde, G.A. Meijer, Losses of chromosome 5q and 14q are associated with favorable clinical outcome of patients with gastric cancer. Oncologist 17, 653–662 (2012)PubMedCrossRef
15.
T.E. Buffart, N.C. van Grieken, M. Tijssen, J. Coffa, B. Ylstra, H.I. Grabsch, C.J. van de Velde, B. Carvalho, G.A. Meijer, High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch. 455, 213–223 (2009)PubMedCentralPubMedCrossRef
16.
R.P. Brosens, J.C. Haan, B. Carvalho, F. Rustenburg, H. Grabsch, P. Quirke, A.F. Engel, M.A. Cuesta, N. Maughan, M. Flens, G.A. Meijer, B. Ylstra, Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. J. Pathol. 221, 411–424 (2010)PubMed
17.
A.S. Hinrichs, D. Karolchik, R. Baertsch, G.P. Barber, G. Bejerano, H. Clawson, M. Diekhans, T.S. Furey, R.A. Harte, F. Hsu, J. Hillman-Jackson, R.M. Kuhn, J.S. Pedersen, A. Pohl, B.J. Raney, K.R. Rosenbloom, A. Siepel, K.E. Smith, C.W. Sugnet, A. Sultan-Qurraie, D.J. Thomas, H. Trumbower, R.J. Weber, M. Weirauch, A.S. Zweig, D. Haussler, W.J. Kent, The UCSC genome browser database: update 2006. Nucleic Acids Res. 34, D590–D598 (2006)PubMedCentralPubMedCrossRef
18.
M.A. Sanz, Treatment of acute promyelocytic leukemia. Hematology. Am. Soc. Hematol. Educ. Program., 147–155 (2006)
19.
J. Voortman, J.H. Lee, J.K. Killian, M. Suuriniemi, Y. Wang, M. Lucchi, W.I. Smith Jr., P. Meltzer, Y. Wang, G. Giaccone, Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc. Natl. Acad. Sci. U. S. A. 107, 13040–13045 (2010)PubMedCentralPubMedCrossRef
20.
N. Deng, L.K. Goh, H. Wang, K. Das, J. Tao, I.B. Tan, S. Zhang, M. Lee, J. Wu, K.H. Lim, Z. Lei, G. Goh, Q.Y. Lim, A.L. Tan, D.Y. Sin Poh, S. Riahi, S. Bell, M.M. Shi, R. Linnartz, F. Zhu, K.G. Yeoh, H.C. Toh, W.P. Yong, H.C. Cheong, S.Y. Rha, A. Boussioutas, H. Grabsch, S. Rozen, P. Tan, A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61, 673–684 (2012)PubMedCentralPubMedCrossRef
21.
A.M. Dulak, S.E. Schumacher, J. van Lieshout, Y. Imamura, C. Fox, B. Shim, A.H. Ramos, G. Saksena, S.C. Baca, J. Baselga, J. Tabernero, J. Barretina, P.C. Enzinger, G. Corso, F. Roviello, L. Lin, S. Bandla, J.D. Luketich, A. Pennathur, M. Meyerson, S. Ogino, R.A. Shivdasani, D.G. Beer, T.E. Godfrey, R. Beroukhim, A.J. Bass, Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 72, 4383–4393 (2012)PubMedCentralPubMedCrossRef
22.
P. Seve, C. Dumontet, Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 9, 168–175 (2008)PubMedCrossRef
23.
P. Seve, J. Mackey, S. Isaac, O. Tredan, P.J. Souquet, M. Perol, R. Lai, A. Voloch, C. Dumontet, Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol. Cancer Ther. 4, 2001–2007 (2005)PubMedCrossRef
24.
G. Ferrandina, G.F. Zannoni, E. Martinelli, A. Paglia, V. Gallotta, S. Mozzetti, G. Scambia, C. Ferlini, Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin. Cancer Res. 12, 2774–2779 (2006)PubMedCrossRef
25.
A. Paradiso, A. Mangia, A. Chiriatti, S. Tommasi, A. Zito, A. Latorre, F. Schittulli, V. Lorusso, Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann. Oncol. 16 Suppl 4, iv14–iv19 (2005)PubMed
26.
N. Urano, Y. Fujiwara, Y. Doki, S.J. Kim, Y. Miyoshi, S. Noguchi, H. Miyata, S. Takiguchi, T. Yasuda, M. Yano, M. Monden, Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int. J. Oncol. 28, 375–381 (2006)PubMed
27.
S.Y. Kanta, T. Yamane, Y. Dobashi, F. Mitsui, K. Kono, A. Ooi, Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum. Pathol. 37, 1333–1343 (2006)PubMedCrossRef
28.
Z. Liang, X. Zeng, J. Gao, S. Wu, P. Wang, X. Shi, J. Zhang, T. Liu, Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer 8, 363 (2008)PubMedCentralPubMedCrossRef
29.
A. Webb, D. Cunningham, J.H. Scarffe, P. Harper, A. Norman, J.K. Joffe, M. Hughes, J. Mansi, M. Findlay, A. Hill, J. Oates, M. Nicolson, T. Hickish, M. O'Brien, T. Iveson, M. Watson, C. Underhill, A. Wardley, M. Meehan, Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. 15, 261–267 (1997)PubMedCrossRef
30.
S. Corporaal, W.M. Smit, M.G. Russel, J. van der Palen, H. Boot, M.C. Legdeur, Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma. Neth. J. Med. 64, 141–146 (2006)PubMed
31.
A.H. Marx, L. Tharun, J. Muth, A.M. Dancau, R. Simon, E. Yekebas, J.T. Kaifi, M. Mirlacher, T.H. Brummendorf, C. Bokemeyer, J.R. Izbicki, G. Sauter, HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol. 40, 769–777 (2009)PubMedCrossRef
32.
C. Bozzetti, F.V. Negri, C.A. Lagrasta, P. Crafa, C. Bassano, I. Tamagnini, G. Gardini, R. Nizzoli, F. Leonardi, D. Gasparro, R. Camisa, S. Cavalli, E.M. Silini, A. Ardizzoni, Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br. J. Cancer 104, 1372–1376 (2011)PubMedCentralPubMedCrossRef
33.
34.
A. Varis, A. Zaika, P. Puolakkainen, B. Nagy, I. Madrigal, A. Kokkola, A. Vayrynen, P. Karkkainen, C. Moskaluk, W. El-Rifai, S. Knuutila, Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int. J. Cancer 109, 548–553 (2004)PubMedCrossRef
35.
M.F. Press, G. Sauter, M. Buyse, L. Bernstein, R. Guzman, A. Santiago, I.E. Villalobos, W. Eiermann, T. Pienkowski, M. Martin, N. Robert, J. Crown, V. Bee, H. Taupin, K.J. Flom, I. Tabah-Fisch, G. Pauletti, M.A. Lindsay, A. Riva, D.J. Slamon, Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J. Clin. Oncol. 29, 859–867 (2011)PubMedCrossRef
36.
L.A. Di, C. Desmedt, J.M. Bartlett, F. Piette, B. Ejlertsen, K.I. Pritchard, D. Larsimont, C. Poole, J. Isola, H. Earl, H. Mouridsen, F.P. O'Malley, F. Cardoso, M. Tanner, A. Munro, C.J. Twelves, C. Sotiriou, L. Shepherd, D. Cameron, M.J. Piccart, M. Buyse, HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. 12, 1134–1142 (2011)CrossRef
37.
A.F. Okines, L.C. Thompson, D. Cunningham, A. Wotherspoon, J.S. Reis-Filho, R.E. Langley, T.S. Waddell, D. Noor, Z. Eltahir, R. Wong, S. Stenning, Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann. Oncol. 24, 1253–1261 (2013)PubMedCrossRef
38.
T. Deng, J.C. Liu, K.I. Pritchard, A. Eisen, E. Zacksenhaus, Preferential killing of breast tumor initiating cells by N, N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine/tesmilifene. Clin. Cancer Res. 15, 119–130 (2009)PubMedCrossRef
39.
L. Reyno, L. Seymour, D. Tu, S. Dent, K. Gelmon, B. Walley, A. Pluzanska, V. Gorbunova, A. Garin, J. Jassem, T. Pienkowski, J. Dancey, L. Pearce, M. MacNeil, S. Marlin, D. Lebwohl, M. Voi, K. Pritchard, Phase III study of N, N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. J. Clin. Oncol. 22, 269–276 (2004)PubMedCrossRef
40.
I.J. Waterman, V.A. Zammit, Differential effects of fenofibrate or simvastatin treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities. Diabetes 51, 1708–1713 (2002)PubMedCrossRef
41.
I.R. Konings, A. van der Gaast, L.J. van der Wijk, F.E. de Jongh, F.A. Eskens, S. Sleijfer, The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial. Eur. J. Cancer 46, 3200–3204 (2010)PubMedCrossRef
42.
43.
G. Chen, M. Rong, D. Luo, TNFRSF6B neutralization antibody inhibits proliferation and induces apoptosis in hepatocellular carcinoma cell. Pathol. Res. Pract. 206, 631–641 (2010)PubMedCrossRef
44.
V. Brinkmann, A. Billich, T. Baumruker, P. Heining, R. Schmouder, G. Francis, S. Aradhye, P. Burtin, Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883–897 (2010)PubMedCrossRef
45.
B.J. Tan, B.H. Tan, G.N. Chiu, Effect of triptolide on focal adhesion kinase and survival in MCF-7 breast cancer cells. Oncol. Rep. 26, 1315–1321 (2011)PubMed
46.
S. Lapenna, A. Giordano, Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 8, 547–566 (2009)PubMedCrossRef
47.
A. Ohtsu, M.A. Shah, C.E. Van, S.Y. Rha, A. Sawaki, S.R. Park, H.Y. Lim, Y. Yamada, J. Wu, B. Langer, M. Starnawski, Y.K. Kang, Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 29, 3968–3976 (2011)PubMedCrossRef
48.
E. Van Cutsem, S. de Haas, Y.K. Kang, A. Ohtsu, N.C. Tebbutt, X.J. Ming, Y.W. Peng, B. Langer, P. Delmar, S.J. Scherer, M.A. Shah, Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J. Clin. Oncol. 30, 2119–2127 (2012)PubMedCrossRef
49.
S.A. Lang, D. Klein, C. Moser, A. Gaumann, G. Glockzin, M.H. Dahlke, W. Dietmaier, U. Bolder, H.J. Schlitt, E.K. Geissler, O. Stoeltzing, Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol. Cancer Ther. 6, 1123–1132 (2007)PubMedCrossRef
50.
L. Xie, X. Su, L. Zhang, X. Yin, L. Tang, X. Zhang, Y. Xu, Z. Gao, K. Liu, M. Zhou, B. Gao, D. Shen, L. Zhang, J. Ji, P.R. Gavine, J. Zhang, E. Kilgour, X. Zhang, Q. Ji, FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin. Cancer Res. 19, 2572–2583 (2013)PubMedCrossRef
51.
J. Lee, J.W. Seo, H.J. Jun, C.S. Ki, S.H. Park, Y.S. Park, H.Y. Lim, M.G. Choi, J.M. Bae, T.S. Sohn, J.H. Noh, S. Kim, H.L. Jang, J.Y. Kim, K.M. Kim, W.K. Kang, J.O. Park, Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol. Rep. 25, 1517–1524 (2011)PubMed
52.
M. Nakajima, H. Sawada, Y. Yamada, A. Watanabe, M. Tatsumi, J. Yamashita, M. Matsuda, T. Sakaguchi, T. Hirao, H. Nakano, The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85, 1894–1902 (1999)PubMedCrossRef
53.
Y.Y. Janjigian, L.H. Tang, D.G. Coit, D.P. Kelsen, T.D. Francone, M.R. Weiser, S.C. Jhanwar, M.A. Shah, MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol. Biomarkers Prev. 20, 1021–1027 (2011)PubMedCentralPubMedCrossRef
Metadata
Title
High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection
Authors
Mariette Labots
Tineke E. Buffart
Josien C. Haan
Nicole C. T. van Grieken
Marianne Tijssen
Cornelis J. H. van de Velde
Heike I. Grabsch
Bauke Ylstra
Beatriz Carvalho
Remond J. A. Fijneman
Henk M. W. Verheul
Gerrit A. Meijer
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 1/2014
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-013-0162-4

Other articles of this Issue 1/2014

Cellular Oncology 1/2014 Go to the issue

Review

Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications

Original Paper

Thymidylate synthase expression and p21WAF1/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy

Review

Clinical application of circulating tumor cells in breast cancer

Original Paper

Genetic gains and losses in oral squamous cell carcinoma: impact on clinical management

Original Paper

Loss of NF2/Merlin expression in advanced sporadic colorectal cancer

Original Paper

A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits